CMS to wind down Medicare drug subsidy program that helped limit some Part D costs

ByDental Info

The Centers for Medicare & Medicaid Services said it would end a prescription-drug subsidy program created in 2024. The effect on beneficiaries will vary.

The Centers for Medicare & Medicaid Services is winding down a Medicare prescription-drug subsidy program that helped lower some beneficiaries’ Part D costs, according to Associated Press reporting.

CMS announced the program would be ended or wrapped up during the week before Aug. 8, 2026. The development could affect prescription costs for Medicare beneficiaries nationwide, although the precise number of people affected and the size of any individual premium changes were not available in the reporting.

What CMS announced

The program was implemented in 2024 after changes made under the 2022 Inflation Reduction Act. Its purpose was to lower some Medicare Part D prescription costs. CMS estimated that the program would cost $3.6 billion in 2026.

The announcement is a decision by the agency to wind down the subsidy program. It should not be described as a legislative repeal unless a formal CMS action says that. The accessible reporting also did not identify the formal CMS notice title or its exact publication date.

That distinction matters because the available information describes an agency program ending or being wrapped up, not a new act of Congress. The next confirmed step is the wind-down itself, while the detailed terms and timing would need to be established in CMS’s underlying announcement.

What it could mean for Medicare beneficiaries

Ending the subsidy could raise prescription costs for some people enrolled in Part D, but it will not necessarily affect every Medicare beneficiary in the same way. Juliette Cubanski, an analyst at KFF, said price increases may be marginal for some beneficiaries and more consequential for others who are already facing multiple cost pressures.

The practical effect will depend on a beneficiary’s coverage and prescription expenses. The approved reporting does not provide a beneficiary count or a specific estimate for how much individual premiums or drug costs could change. It therefore does not support saying that every beneficiary will pay more.

CMS had previously announced that average standalone Medicare prescription-plan premiums for 2026 would be about $34.50. That figure was nearly 10% lower than the prior year’s average. The premium figure provides broader 2026 Part D cost context, but it does not establish what any particular beneficiary will pay after the subsidy program is wound down.

Part of a wider affordability debate

The change comes as federal health-care affordability remains under pressure from several directions. AP reported that the subsidy decision is part of a broader set of changes that includes Medicaid reductions and the expiration of Affordable Care Act subsidies.

Those developments involve different programs and should not be treated as a single policy change. Together, however, they shape the cost and coverage environment facing people who rely on public or subsidized health insurance.

For Medicare beneficiaries, the immediate question is how CMS will implement the wind-down and whether the agency’s formal notice provides more detail about affected plans, costs and timing. Those details were not available in the accessible AP result reviewed for this report.

The program’s estimated 2026 price tag was $3.6 billion, but no specific national savings figure has been established in the approved materials. Until CMS publishes or identifies the underlying notice, the financial effect on beneficiaries and the federal government remains only partly defined.

Sources

Related